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DNA transcription, replication, and repair are regu-
lated by histone acetylation, a process that requires
the generation of acetyl-coenzyme A (CoA). Here,
we show that all the subunits of the mitochondrial
pyruvate dehydrogenase complex (PDC) are also
present and functional in the nucleus of mammalian
cells. We found that knockdown of nuclear PDC in
isolated functional nuclei decreased the de novo
synthesis of acetyl-CoA and acetylation of core
histones. Nuclear PDC levels increased in a
cell-cycle-dependent manner and in response to
serum, epidermal growth factor, or mitochondrial
stress; this was accompanied by a corresponding
decrease in mitochondrial PDC levels, suggesting a
translocation from the mitochondria to the nucleus.
Inhibition of nuclear PDC decreased acetylation of
specific lysine residues on histones important for
G1-S phase progression and expression of S phase
markers. Dynamic translocation of mitochondrial
PDC to the nucleus provides a pathway for nuclear
acetyl-CoA synthesis required for histone acetylation
and epigenetic regulation.
INTRODUCTION
Epigenetic regulation of gene expression is essential for
embryonic development and differentiation, protection against
viruses, and progression of cancer (Jaenisch and Bird, 2003). It
includes modifications of core histones by either methylation
or acetylation. By neutralizing the positive charges of lysine res-
idues in histones, acetylation promotes the relaxation of DNA,
necessary for replication and transcription (Vogelauer et al.,
2002). A recent high-resolution mass spectrometry analysis
identified a large number of nuclear proteins with multiple acet-
ylation sites, suggesting that the role of acetylation extends
beyond histones (Choudhary et al., 2009). In eukaryotes, the84 Cell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc.biosynthesis of acetyl-coenzyme A (CoA) is thought to occur in
the subcellular compartment where it is required, because it is
membrane impermeable and very unstable, due to the high-
energy thioester bond that joins the acetyl and CoA groups.
Our understanding of how the nucleus generates acetyl-CoA in
metazoan cells is incomplete. Acetyl-CoA synthetase (AceCS1)
and ATP-citrate lyase (ACL) are both present in the nucleus
(Wellen et al., 2009). ACL is the predominant pathway for
nuclear acetyl-CoA generation in mammalian cells because it
utilizes glucose-oxidation-derived mitochondrial citrate as its
substrate, as opposed to AceCS1, which uses acetate, a fuel
that is not an important energy source for mammalian cells
(Wellen et al., 2009). However, in cells with decreased citrate
levels due to mitochondrial suppression by Bcl-xL overexpres-
sion, levels of acetyl-CoA and N-a-acetylated proteins
decreased in the cytoplasm with no apparent decrease in
histone acetylation (Yi et al., 2011). This suggested the presence
of a yet unidentified mitochondria-independent mechanism for
histone acetylation in the nucleus.
Primitive protozoan cells that lack mitochondria, like
Entamoeba histolytica, utilize pyruvate:ferrodoxin oxidoreduc-
tase (PFO) to generate acetyl-CoA (Rodrı´guez et al., 1998).
Mammalian cells do not express PFO but generate acetyl-CoA
in mitochondria with a similar complex of nucleus-encoded pro-
teins known as pyruvate dehydrogenase complex (PDC) (Horner
et al., 1999). The generation of acetyl-CoA from both PFO and
PDC is dependent on the glycolysis-derived product pyruvate.
The nuclear presence of several metabolic enzymes has been
observed as early as the 1960s, with many shown to interact
with nuclear proteins and DNA and ‘‘moonlight’’ to the nucleus
in conditions of cellular stress (Kim and Dang, 2005; Siebert
and Humphrey, 1965; Yang et al., 2012; Yogev et al., 2010).
For example, the M2 isoform of the glycolytic enzyme pyruvate
kinase (PKM2) translocates to the nucleus and functions as a
protein kinase, phosphorylating nuclear proteins, like threo-
nine-11 of histone 3 (H3), and enhancing the acetylation of lysine
9 on H3 (H3K9) (Yang et al., 2012). The protein kinase function of
PKM2 utilizes the glycolytic intermediate phosphoenolpyruvate
(PEP) and not ATP as its phosphate donor (Vander Heiden
et al., 2010), resulting in the subsequent generation of pyruvate
(Gao et al., 2012; Yang et al., 2012). However, the fate of
pyruvate in the nucleus and whether this is related to the
acetyl-CoA used in the H3K9 acetylation remain unknown.
Intact and functional PDC can translocate across mitochon-
drial membranes from the matrix to the outer mitochondrial
membrane (Hitosugi et al., 2011). Thus, it would be possible for
a chaperone protein to bind PDC from the outer mitochondrial
membrane and bring it to the nucleus under conditions that
stimulate S phase entry and cell-cycle progression, where his-
tone acetylation is critical.
We provide evidence that supports the hypothesis that func-
tional PDC can translocate from the mitochondria to the nucleus
during cell-cycle progression, generating a nuclear pool of
acetyl-CoA from pyruvate and increasing the acetylation of
core histones important for S phase entry. The mitochondrial
pyruvate dehydrogenase kinase (PDK), which phosphorylates
and inhibits mitochondrial PDC, was not detectable in the nu-
cleus, suggesting that nuclear PDC may be constitutively active
and regulated differently than mitochondrial PDC. The nuclear
translocation of PDCwas triggered by growth signals, like serum
and epidermal growth factor, or mitochondrial inhibitors, like
rotenone. Nuclear PDC provides a means for the nucleus to
generate acetyl-CoA in an autonomous fashion. The implications
of this work extend tomany conditions where nuclear acetylation
is altered, like development, cancer, neurodegeneration, or car-
diovascular disease.
RESULTS
All Components of PDC Are Present in the Nucleus
PDC is comprised of subunits from three catalytic enzymes:
pyruvate dehydrogenase (E1), dihydrolipoamide transacetylase
(E2), and dihydrolipoamide dehydrogenase (E3), as well as the
tethering protein, E3-binding protein (E3BP) (Behal et al.,
1993). We first identified the nuclear presence of PDC-E1
(a subunit) in human spermatozoa, which compartmentalize
the nucleus (in the head) away from mitochondria (in the
midsection), allowing for more clear visualization of nuclear
versus mitochondrial PDC (Figure S1A available online). To
confirm the nuclear presence of PDC-E1 in a terminally differ-
entiated primary cell line, we isolated primary fibroblasts from
human lungs and detected its nuclear presence (Figure 1A).
We then performed a more-detailed assessment for the pres-
ence of nuclear PDC using microscopy in two commercially
available cell lines, normal small airway epithelial cells (SAEC)
and A549 cells (non-small-cell lung cancer cells). In intact
SAEC and A549 cells costained with an antibody against
PDC-E1 and the mitochondrial marker MitoTracker Red, coloc-
alization of the two signals was evident in the cytoplasm as
expected, but PDC-E1 was also evident within the nucleus
(marked by DAPI) without any mitochondrial signal (Figures
1B and 1C). For our imaging, we generated 25 separate im-
ages in each intact cell, systematically scanning in the z axis
at 0.2 mm in depth for each image. We used these stacked im-
ages to generate 3D videos that show the presence of PDC-E1
throughout the nucleus (Movies S1 and S2). We selected spe-
cific planes that ‘‘cut through the nucleus’’ from the z stacked
images, as shown in the top image of Figure 1D. Then, in theXY axis, we quantified the nuclear PDC-E1 and MitoTracker
Red signals by measuring the fluorescence intensity. As we
move from left to right in the image plane, an area of mito-
chondria is followed by an area where only the nucleus is
present. PDC-E1 is highly detected in the mitochondria and
colocalizes with the MitoTracker Red signal. However,
whereas the MitoTracker Red signal intensity is absent in the
nucleus, the PDC-E1 signal is present, though with lesser in-
tensity than the mitochondrial PDC-E1 signal (Figure 1D).
Furthermore, nuclear PDC-E1 followed a similar signal pattern
to the nuclear protein histone 3, confirming the specificity of
the nuclear PDC-E1 signal (Figure S1B). In addition, a clear nu-
clear signal of PDC-E1 was also detected in the nucleus using
electron microscopy (Figure S1C). These data show that the
nuclear PDC-E1 signal is not a ‘‘contamination’’ from overlap-
ping mitochondria.
To address the possibility that our PDC-E1 antibody nonspe-
cifically binds to other nuclear proteins, we transfected A549
and SAEC with a plasmid encoding for cloned human E1a
subunit of PDC in frame with enhanced GFP (EGFP). Based on
EGFP fluorescence, we detected the presence of the fused
EGFP-E1 protein in mitochondria as well as the nucleus of
both cell types (Figures 1E and S1D). We then identified the
nuclear presence for other subunits of the PDC complex,
including PDC-E2, PDC-E3, and the ancillary subunit PDC-
E3BP in intact cells using immunofluorescence (Figures 1F–
1H). For all confocal and electron microscopy experiments, a
‘‘secondary antibody-only’’ control staining was performed,
which in all experiments showed no signal (Figure S1E).
Nuclear PDC Is Functional and Can Generate Acetyl-
CoA from Pyruvate
To assess if nuclear PDC is functional, we isolated nuclei using
a nuclei-specific, high-sucrose gradient centrifugation protocol.
As even a small amount of mitochondrial membranes could be
a confounding factor, we took several steps to ensure that our
nuclei were not contaminated with any mitochondria. We
showed that nuclear membranes were intact by the lamin-
staining pattern and that our nuclear preparations were free
of mitochondrial membranes, as assessed by nonyl-acridine
orange (NAO) and MitoTracker Red imaging (Figures 2A and
2B), as well as free of cytoplasmic, mitochondrial matrix,
and membrane proteins, as assessed by immunoblots with
antibodies against a-tubulin, citrate synthase (CS), isocitrate
dehydrogenase 2 (IDH2), succinyl-CoA synthetase (SCS), and
succinate dehydrogenase (SDH) (Figure 2C). These vigorous
purity indices were used in all of our experiments with isolated
nuclear preparations throughout this work. In these pure nuclei
preparations, we confirmed the presence of PDC-E1 in
nuclei from the EGFP-transfected cells, as well as from intact
nuclei from A549 and SAEC cells, using immunofluorescence,
with absence of any detectable signal in secondary-only anti-
body straining (Figure S2A, upper panels). In addition to the a
subunit of the PDC-E1, all the subunits of the PDC complex
were present in isolated nuclei (Figure S2A, bottom panels).
We then used immunoblots and showed the nuclear presence
of all PDC subunits in isolated nuclei from A549 cells (Figure 2D)
as well as a separate cancer cell line, 786-O renal cellCell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc. 85
Figure 1. PDC Is Present in the Nucleus of Human Cells
(A–C) Primary fibroblasts (A), small airway epithelial cells (SAECs) (B), and A549 cells (C) were costained with an antibody to the a subunit of PDC-E1 (green), the
mitochondrial markerMitoTracker Red (red), and either the nuclearmarker DAPI (blue for A andB) or histone 3 (purple for C). The arrow shows PDC-E1 localized in
the nucleus in the absence of a mitochondrial signal.
(D) An A549 cell was costained with PDC-E1 (green) andMitoTracker Red (red) and scanned at 0.2 mm increments along the z axis using confocal microscopy (top
image). The fluorescence intensities midlane in the cell in the XY axis are shown (top and middle images).
(E) A549 cells were transfected with a plasmid encoding for EGFP-PDC-E1 and costained with MitoTracker Red and DAPI. EGFP-PDC-E1 is clearly seen in the
nucleus (white arrow).
(F–H) A549 cells were costained with PDC-E2 (F), PDC-E3 (G), and PDC-E3BP (H) (all in green); MitoTracker Red; and lamin (purple). The images were taken at the
midplane of the cell and clearly show the nuclear presence of PDC (white arrow).
See also Figure S1.carcinoma cells, in the absence of cytoplasmic or mitochon-
drial contamination (Figure 2E). As NAD(H) is abundant in the
nucleus, our finding that PDC-E2 appears to be lipoylated
(implying the nuclear presence of lipoic acid; not present in
our media), suggests that nuclear PDC has all the necessary
cofactors to be functional (Figure S2B).
To study the function of nuclear PDCwithout interference from
mitochondrial PDC, we performed our initial experiments on
isolated nuclei. We detected many glycolytic intermediates,
including PEP, pyruvate, and acetyl-CoA, using collision-
induced dissociation mass spectrometry (Figure 2F). We then
designed an experiment to study whether nuclear PDC is func-
tional in terms of the de novo biosynthesis of acetyl-CoA.86 Cell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc.We first isolated intact and pure nuclei from either A549 or
786-O cells previously treated with scrambled versus PDC-E1
small interfering RNA (siRNA). We obtained an efficient knock-
down of PDC-E1, resulting in no detectable immunoblot signal
(Figure 2G, top). This was in keeping with the absence of any
PDC activity in nuclei lacking PDC, measured by a standard
dipstick assay that measures the NADH produced by the immu-
nocaptured enzyme (Figure 2G, bottom).
We then treated these nuclei with an isotope-labeled form of
pyruvate (13C2-pyruvate) for 8 hr and measured the production
of labeled acetyl-CoA (13C1-acetyl-CoA; Figure 2H). Because
the only way to synthesize acetyl-CoA from pyruvate is by
PDC, the detection of labeled acetyl-CoA in our nuclear
Figure 2. Nuclear PDC Is Functional and Can Synthesize Acetyl-CoA
(A and B) The mitochondrial membrane markers nonyl-acridine orange- (NAO; green; A) and MitoTracker Red- (B) stained whole cells, but signal was not
detectable in isolated nuclei preparations. Nuclei were stained with lamin (purple) or DAPI (blue).
(C) Our isolated nuclear preparations had no detectable levels of the cytoplasmic marker a-tubulin and mitochondrial markers citrate synthase (CS), isocitrate
dehydrogenase 2 (IDH2), succinyl-CoA synthetase (SCS), and succinate dehydrogenase (SDH) (an example from A549 cells is shown).
(D and E) Immunoblots showing that all subunits of PDC were present in isolated pure nuclei of A549 and 786-O cells.
(F) Many glycolytic intermediates, including phosphoenolpyruvate (PEP), pyruvate, and acetyl-CoA (red), were detected in isolated nuclei from A549 cells, using
collision-induced mass spectrometry.
(G) There was no detectable PDC-E1 protein (immunoblot, top) or enzymatic activity measured by a dipstick assay from nuclei isolated from PDC-E1 siRNA-
treated cells.
(H) Mechanism for the 13C2-pyruvate experiments.
(I) Isolated nuclei from A549 or 786-O cells previously treated with either PDC-E1 or scrambled siRNA were incubated with 13C2-pyruvate for 8 hr. The nuclei
lacking PDC-E1 had decreased levels of 13C1-acetyl-CoA compared to scrambled siRNA controls, measured by mass spectrometry, and normalized to protein
concentration. Increasing doses of labeled pyruvate showed a dose-dependent increase in labeled acetyl-CoA.
Error bars represent SEM. See also Figure S2.preparations reflects the activity of nuclear PDC. We detected a
significant decrease in the levels of 13C1-labeled acetyl-CoA in
nuclei from PDC-E1 siRNA-treated cells compared to those
from scrambled siRNA, using two separate mass spectrometry
acquisition modes in A549 and 786-O nuclei (Figures 2I and
S2C). We also detected increasing levels of labeled acetyl-CoA
in response to increasing levels of labeled pyruvate, suggesting
the presence of nonlimiting amounts of functional PDC in the iso-
lated nuclei (Figures 2I and S2C).Nuclear PDC Is Important for Histone Acetylation
We then assessed whether the acetyl-CoA generated from
nuclear PDC is important for histone acetylation. Because his-
tone acetylation depends on glucose and not free fatty acid
metabolism (Wellen et al., 2009), we first deprived the A549 cells
of glucose for 24 hr in order to synchronize acetylation, in the
presence of scrambled or PDC-E1 siRNA. Next, we isolated
functional nuclei from scrambled and PDC-E1 siRNA-treated
cells, exposed them to pyruvate (10 mM) for 8 hr, and measuredCell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc. 87
Figure 3. PDC Is Important for Histone Acetylation
(A) Experimental design for acetylation experiments in isolated nuclei.
(B) In the absence of pyruvate at time = 0, there were no differences in acetyl-lysine of proteins within the molecular weight of acetylated histones (n = 3
experiments) between nuclei isolated from PDC-E1 siRNA or scramble-treated cells.
(C) Nuclei lacking PDC-E1 exposed to 10 mM pyruvate for 8 hr had decreased levels of acetylated H2B, H3, and H4, compared to control. Lamin and Ponceau
S were loading controls. Representative immunoblots are shown to the left, and quantified mean data normalized to lamin are shown to the right (n = 3
experiments; *p < 0.05).
(D) PDC-E1 and ACL siRNA-treated A549 cells had almost complete knockdown of PDC-E1 and ACL, respectively, compared to scrambled siRNA-treated cells
(top). Extracted histones from PDC-E1 and ACL siRNA-treated A549 cells exposed to 10 mM glucose had decreased levels of acetylated H2B, H3, and H4
compared to scrambled siRNA control (bottom). Quantified mean data (to total H3) are shown on the right (n = 3 experiments).
Error bars represent SEM. See also Figure S3.histone acetylation (Figure 3A). Prior to the addition of pyruvate
to our isolated nuclei (time = 0), no significant differences were
apparent in acetylated lysine levels at the molecular weight of
histones between scrambled and PDC-E1 siRNA groups (Fig-
ure 3B), confirming the synchronization of acetylation. After
exposure to pyruvate, nuclei from PDC-E1 siRNA-treated cells
had decreased levels of all three acetylated (Ac) core histones
H2B, H3, and H4, compared to nuclei from scrambled siRNA-
treated cells (Figure 3C).
On the other hand, inhibition of nuclear PDC did not appear
to change the acetylation of p53 and FOXO1 in these cancer
cells, suggesting that the acetylation of targets in the
nucleus is regulated, perhaps by the availability or proximity of
acetyl-transferases or deacetylases with acetyl-CoA-generating
enzymes, like PDC (Figure S3). Alternatively, a rapid turnover of
acetyl groups in histones, compared to those of other proteins,88 Cell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc.may also explain why the inhibition of nuclear PDC preferentially
showed a decrease in histone acetylation.
Because the role of ACL on nuclear acetylation has not been
studied in A549 cells, we used ACL or PDC-E1 siRNA in order
to study the relative importance of these two enzymes in
nuclear acetylation. Extracted histones from either PDC-E1
or ACL siRNA-treated cells had decreased histone acetylation
compared to scrambled siRNA-treated cells (Figure 3D).
Nevertheless, in these cells, the impact of PDC-E1 silencing
on histone acetylation appears to be larger than that of ACL
silencing. This may be explained by the fact that PDC is also
involved in the ACL-mediated production of nuclear acetyl-
CoA, as mitochondrial PDC is also an important regulator of
citrate production (i.e., ACL’s substrate) via the Krebs cycle.
The effects of ACL and PDC-E1 silencing were not the same
on the acetylation of specific histones, suggesting that the
Figure 4. Nuclear PDC Is Regulated Differently Than Mitochondrial PDC
(A) A549 cells have high levels of PDKI and PDKII in isolated mitochondria, but no detectable levels in isolated nuclei. Phosphorylated PDC-E1 serine-293
was present in isolated mitochondria (where PDK is present), but not in isolated nuclei (where PDK is absent), and the ratio of P-E1/E1 is shown below.
Confocal microscopy shows the presence of PDKII (green) in the mitochondria as assessed by colocalization (yellow) with MitoTracker Red in the merge
panel, but not in the nucleus, stained with DAPI (blue; upper right). Immunoblot showing that PDPI, but not PDPII, is present in isolated nuclei from A549 cells
(bottom right).
(B) In 786-O cells, PDKI (but not PDKII) is present in whole cell preparations, but not in isolated nuclei (left). The absence of PDK in the nucleus is confirmed by
confocal microscopy (top right). PDPI, but not PDPII, is present in isolated nuclei from 786-O cells (bottom right).
(C) A549 cells had higher levels phosphorylated serine-293 on PDC-E1 compared to isolated mitochondria from normal SAECs.
(D) Extracted histones from isolated A549 (left) and 786-O (right) nuclei exposed to DCA (5 mM) had similar levels of acetylated H3 compared to vehicle-treated
control cells.
(E) In contrast, DCA increased the acetylation of H3 (left) and tubulin (right) in whole A549 cells, reflecting the activation of mitochondrial PDC. Representative
immunoblots (top) and quantified mean data normalized to total H3 (left) or tubulin (right) are shown (n = 4 experiments; *p < 0.05).
(F) Mechanism for DCA-mediated increase in acetylation (see Results section for discussion).
Error bars represent SEM. See also Figure S4.source of acetyl-CoA may play a role in which target is
acetylated.
Pyruvate Dehydrogenase Kinase Is Not Present in the
Nucleus
Mitochondrial PDC-E1 is tonically inhibited by PDKs and acti-
vated by PDC phosphatases (PDPs). PDKs phosphorylate
serine-293 of the a subunit of PDC-E1, resulting in its inactivation
(Behal et al., 1993). Whereas PDK I and II are ubiquitously ex-
pressed, PDK III and IV are only expressed in the testis and under
starvation conditions in muscle, respectively (Bowker-Kinley
et al., 1998). Hypoxia-inducible factor 1a (HIF1a) is activated in
many cancers and can suppress mitochondrial PDC by inducing
PDK expression (Kim et al., 2006). We detected PDKI and II in
mitochondria, but not in isolated nuclei of A549 (which expressboth isoforms) and 786-O cancer cells (which only express
PDKI; Figures 4A and 4B). On the other hand, we detected the
presence of PDPI (but not PDPII) in nuclei of A549 and 786-O
cells (Figures 4A and 4B). We found higher levels of PDC-E1
serine-293 phosphorylation in A549 mitochondria compared to
normal cells (Figure 4C), in keeping with the finding that cancer
cells have higher levels of PDK (Michelakis et al., 2010). Further-
more, PDC-E1 phosphorylated serine-293 was present in mito-
chondria, but not in nuclei (Figure 4A), in keeping with the
absence of PDK. This suggested that, in certain conditions
(like in cancer or hypoxia, where HIF1a is activated), whereas
mitochondrial PDC can be relatively inactive, nuclear PDC could
remain constitutively active.
We then treated isolated nuclei from A549 and 786-O cancer
cells with the small-molecule PDK inhibitor dichloroacetateCell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc. 89
(DCA), which primarily inhibits PDK I and II (Bonnet et al., 2007;
Michelakis et al., 2010) and showed no differences in Ac-H3
levels (Figure 4D). However, DCA treatment of whole A549 cells
resulted in both increased Ac-H3 (nuclear acetylation) and Ac-
tubulin (cytoplasmic acetylation; Figures 4E, S4A, and S4B).
The increase in acetylation by DCA in whole cells may be due
to acetyl-CoA biosynthesis by cytoplasmic and nuclear ACL,
which produces acetyl-CoA using citrate as substrate (Fig-
ure 4F). We confirmed the expected DCA-induced increase in
citrate, along with another Krebs cycle intermediate (succinate)
and the expected decrease in lactate (Figure S4C). Thus, the
differential effects of DCA (which has known anticancer proper-
ties; Bonnet et al., 2007; Dhar and Lippard, 2009; Michelakis
et al., 2010) between mitochondrial and nuclear PDC reflect
the differential expression of PDK in the two cellular compart-
ments and suggest that factors that can increase or decrease
PDK function (like HIF1a and DCA, respectively) can be used
to exploit the functional significance of nuclear PDC, an idea
that we explored later on.
PDC Translocates from theMitochondria to the Nucleus
during S Phase
To study whether histone acetylation occurs prior to DNA repli-
cation during S phase in our cells, we first synchronized cells
to the G1 phase by serum starvation for 24 hr. We then intro-
duced serum and serially measured Ac-H3 and cyclin A. Ac-H3
levels increased first, followed by cyclin A (Figure 5A). By
isolating pure nuclei from these cells, we also showed that
nuclear PDC-E1 levels followed a similar increase pattern to
Ac-H3 and then began to decrease toward baseline, but only
after Ac-H3 levels peaked (Figure S5A). Furthermore, using
microscopy, we showed that both PDC-E1 and Ac-H3 were
higher during late S phase compared to baseline in isolated
nuclei (Figure S5B).
We then measured both nuclear and mitochondrial PDC-E1
levels upon serum stimulation after cell cycle synchronization,
at the same time points. We found that the increase in nuclear
PDC-E1 levels during cell-cycle progression was associated
with a parallel decrease in mitochondrial PDC-E1 levels, before
both PDC fractions returned toward their baseline levels (Fig-
ure 5B). The decrease in mitochondrial PDC was not due to
enhanced degradation because PDC levels remained unaltered
in whole cells in response to increasing concentrations of serum
(Figure S5C), suggesting the decrease inmitochondrial PDCwas
due to its translocation to the nucleus.
To measure the relative distribution of PDC in the mitochon-
dria and nucleus, we loaded on the same gel the same amount
of protein from isolated nuclei and mitochondria at baseline
and 3 hr postserum stimulation. Although PDC-E1 levels
were clearly higher in mitochondria than the nuclei, the percent
ratio of nuclear to mitochondrial PDC-E1 increased from 17%
to 30% after 3 hr of serum stimulation (Figure S5D). A similar
increase in the percent ratio of nuclear to mitochondrial PDC
in response to serum stimulation was also observed with the
E2 component using immunofluorescence, where we were
able to measure mitochondrial PDC (overlap with MitoRed)
and nuclear PDC (overlap with DAPI) within the same cell
(Figure 5C).90 Cell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc.We then performed a series of experiments to further support
the fact that nuclear PDC translocates from themitochondria. To
exclude the possibility that the increase in nuclear PDC in
response to serum stimulation is a newly translated product
from the endoplasmic reticulum (ER), we inhibited ribosomal
translation with cycloheximide (CHX) and measured nuclear
PDC levels (see Figure 5D). Serum stimulation increased nuclear
PDC (E1 and E2), and this was not altered by CHX, although the
translation of c-myc (a protein with a short half-life, previously
shown to be decreased within 2 hr of CHX treatment; Alarcon-
Vargas et al., 2002) was decreased during this timeframe
(Figure 5E).
Newly synthesized mitochondrial proteins from the ER
contain an N terminus mitochondrial localization sequence
(MLS), and upon entry into the matrix, the MLS is cleaved by
the mitochondrial-processing peptidase (MPP; see Figure 5D).
The cleavage of these (otherwise destabilizing) sequences
(15–50 amino acids) of mitochondrial proteins is required to
prevent degradation and facilitate subsequent assembly of
subunits (Chacinska et al., 2009). Only mature (cleaved MLS)
PDC proteins are able to refold and form complexes in the mito-
chondria. Therefore, we hypothesized that, if nuclear PDC is
directly translocated to the nucleus after its translation in ribo-
somes, we should be able to detect the precursor form in the
nucleus. Using two separate siRNA transfection approaches
for the b-catalytic subunit of MPP, we were able to inhibit the
mRNA levels by 65% and 90%, respectively, resulting in the
accumulation of increasing levels of the precursor form of
PDC-E1 (Figure 5F, see arrowhead) along with the mature
form. We then usedMPP siRNA-treated whole cells and probed
for PDC-E1 on the same membrane with isolated nuclei and
mitochondrial protein from untreated cells. Whereas the precur-
sor form was clearly seen in the MPP-silenced whole cells in the
same gel, only the mature form of PDC was detected in isolated
nuclei and mitochondria (Figure 5G, top). We also isolated
nuclei from both scrambled and MPP siRNA-treated cells and
could not detect the presence of the precursor; only mature
PDC was present in the nucleus (Figure 5G, bottom). As MPP
is a mitochondria-specific protease, our data suggest that
nuclear PDC is processed in the mitochondria prior to translo-
cation to the nucleus.
All of the subunits of PDC are translated in the ER and are
transported separately to the mitochondria, where they are pro-
cessed prior to complex formation. We hypothesized that, if we
inhibit only one of the subunits and thus disturb the stoichiometry
balance of the subunits within the complex, we may affect the
nuclear levels of the other subunits. Indeed, knockdown of only
PDC-E1 by siRNA resulted in decreased levels of all catalytic
components of PDC in the nucleus, without changing their over-
all protein expression in whole cell preparations (Figure S5E).
This suggests that PDC is translocated from the mitochondria
to the nucleus as a functional complex.
Signals Increasing Nuclear PDC Levels
We then studied signals that may trigger the nuclear transloca-
tion of PDC. Epidermal growth factor (EGF) signaling is impor-
tant for S phase entry and cell-cycle progression (Kato et al.,
1998) and has been shown to increase the nuclear translocation
Figure 5. PDC Is Translocated from the Mitochondria to the Nucleus
(A) Serum stimulation time course after cell-cycle synchronization in G1 phase showed an early increase in acetylation of H3, followed by an increase in the S
phase marker cyclin A. Representative immunoblots are shown above. The rate of acetylation of H3 is faster than cyclin A expression within the first 4 hr after
introduction of serum. Note the brake in the time scale, showing a later relative plateau in H3 acetylation, whereas cyclin A levels continue to increase (n = 3
experiments; *p < 0.001 for Ac-H3 compared to cyclin A slopes).
(B) Serum stimulation time course shows an increase in nuclear levels of PDC-E1 peaking at 3 or 4 hr, associated with a parallel decrease in mitochondrial PDC-
E1. This was followed by a return toward baseline levels of both the mitochondrial and nuclear PDC levels. Representative immunoblots are shown above, and
quantified data normalized to either lamin (nuclei) or CS (mitochondria) are shown below (n = 4 experiments).
(C) A549 cells were costained with PDC-E2 (green), MitoTracker Red (red), and DAPI (blue). The mitochondrial E2 signal was quantified by signal overlap with
MitoTracker Red, whereas nuclear signal was quantified by signal overlap with DAPI in the same cell, and the ratio of the two for each cell was calculated. Serum
stimulation increased the nuclear to mitochondrial ratio, suggesting nuclear translocation from mitochondria (n = 25 cells; *p < 0.05).
(D) Experimental design for the study of nuclear PDC translocation using cycloheximide (CHX) and gene silencing of MPP.
(E) In response to serum stimulation (4 hr), nuclear PDC-E1 and PDC-E2 increased, and this was not altered by CHX, which decreased the levels of c-myc.
(F) Using two siRNA transfection approaches to silence MPP, we found a clear signal of the unprocessed (precursor) form of PDC-E1 (arrowhead). Lamin was
used as a loading control. Quantitative RT-PCR (qRT-PCR) shows the relative fold change for bothMPP siRNA transfection approaches. Note that more-effective
silencing (transfection 2) resulted in higher levels of the PDC-E1 precursor.
(G) The PDC-E1 precursor was not detected in protein from isolated nuclei ormitochondria loaded in the same gel with whole cell protein fromMPP siRNA-treated
cells, which clearly showed the presence of the precursor (top; arrowhead shows precursor form). The precursor PDC-E1 was not detectable in nuclei isolated
from the MPP siRNA-treated cells (arrowhead represents where the precursor band would have been detected).
Error bars represent SEM. See also Figure S5.of PKM2 in cancer (Yang et al., 2012). We found that recombi-
nant human EGF (rhEGF) increased the nuclear levels of PDC
components, along with PKM2, in A549 cells (Figures 6A and
S6A). The increase in nuclear levels was through translocation
because rhEGF did not change the total cellular expression of
PDC subunits, whereas it predictably increased tyrosine-204phosphorylation of mitogen-activated protein kinase (MAPK)
(Figure 6B). Similarly, gefitinib, an EGF receptor inhibitor,
decreased nuclear (Figure 6C), but not whole cell PDC levels
(Figure 6D). We then used confocal imaging and studied the
relative distribution of PDC subunits within the same cell, in
786-O cells. Similar to A549 cells, rhEGF increased the relativeCell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc. 91
Figure 6. Signals Increasing the Nuclear Translocation of PDC
(A and B) Isolated nuclei from rhEGF-treated A549 cells have increased levels of PDC-E1, E2, and E3 compared to the vehicle-treated cells (n = 3 experiments;
*p < 0.05; A), without changing total cellular levels, whereas rhEGF treatment increased tyrosine-204 phosphorylation of MAPK (B). Lamin and actin were used as
loading controls.
(C and D) Gefitinib decreased nuclear levels of all three PDC subunits, as shown by immunoblots, without changing the total cellular expression.
(E) 786-O cells were costained with PDC-E2 (green), MitoTracker Red (red), and DAPI (blue). Serum stimulation increased the nuclear to mitochondrial ratio,
compared to serum-free treated cells; this was enhanced by rhEGF and further enhanced by the addition of rotenone (5 mM; n = 25 cells; *p < 0.05 compared to
serum free; **p < 0.05 compared to vehicle; #p < 0.05 compared to rhEGF). A similar pattern was seen in PDC-E1translocation (representative images shown in
Figure S6B).
(F) Hsp70 coimmunoprecipitates with PDC-E1 and PDC-E2, but not with PDKI, in A549 cells. Input represents 2.5 mg of whole cell lysate. IP, immunoprecipitation.
(G) Serum-stimulated (4 hr) A549 cells pretreated with KNK437 (100 mM) show decreased nuclear levels of both Hsp70 and PDC-E1 compared to vehicle (DMSO)-
treated cells. Mean data are normalized to Ponceau S (n = 3 experiments; *p > 0.05).
(H) The same cells as in (G) were costained with Hsp70 and PDC-E1, imaged with confocal microscopy, and the nuclear fluorescence intensity was measured. A
Pearson product-moment correlation plot showed that nuclear levels of Hsp70 and PDC-E1 correlate positively (r = 0.66; p < 0.001; n = 50 cells/group).
Representative images are shown in Figure S6H. AFU, arbitrary fluorescence units.
(I) Serum-stimulated (4 hr) A549 cells transfected with Hsp70 siRNA show decreased nuclear levels of both Hsp70 and PDC-E1, compared to scrambled-
transfected cells.
Error bars represent SEM.distribution of PDC-E1 and PDC-E2 from themitochondria to the
nucleus (Figure 6E).
We speculated that a mitochondrial stressor might trigger
translocation of PDC from the mitochondria to the nucleus.
We studied the electron transport chain (ETC) complex I inhib-
itor rotenone, because inhibition of ETC complexes is a well-
known cause of mitochondrial stress (Durieux et al., 2011).
We found that rotenone caused a significant translocation of92 Cell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc.PDC into the nucleus over and above serum and rhEGF (Fig-
ures 6E and S6B). Mitochondria adapt to stress by initiating
the mitochondria unfolded protein response, which results in
increased expression of mitochondrial import proteins, folding
chaperones and heat shock proteins, amplifying the communi-
cation with the nucleus (Zhao et al., 2002). We speculated that
a heat shock chaperone may be involved in the nuclear trans-
location of PDC.
We studied heat shock protein 70 (Hsp70) based on evidence
that (1) induction of Hsp70 is cell cycle dependent, with its
highest expression and nuclear localization observed during S
phase (Milarski and Morimoto, 1986), (2) Hsp70 is involved in
the nuclear translocation of several proteins (Shi and Thomas,
1992), and (3) Hsp70 binds to and activates mitochondrial PDC
(Kiang et al., 2006). We confirmed that nuclear levels of Hsp70
increase in a cell-cycle-dependent manner, similarly to the in-
crease in nuclear PDC-E1 following serum stimulation (Fig-
ure S6C). We performed immunoprecipitation studies on A549
cells and MRC-9 cells (fibroblasts) with Hsp70 and detected
the presence of PDC-E1 and PDC-E2 (Figures 6F and S6D),
suggesting that Hsp70 may bind to these components of the
complex. Sequence and structural analysis of potential binding
motifs for Hsp70 within the PDC complex showed a putative
Hsp70-binding motif (i.e., hydrophobic peptide regions; Mayer
and Bukau, 2005) within the PDK-binding site on PDC
(Figure S6E). PDK did not coimmunoprecipitate with Hsp70 (Fig-
ures 6F and S6D), suggesting that Hsp70 and PDKmay compete
for similar binding domains within PDC.
We pretreated serum-starved A549 and 786-O cells with either
vehicle (DMSO) or KNK437, an inhibitor of heat shock factor 1,
which results in decreased expression of inducible Hsp70 (Koishi
et al., 2001), prior to serum stimulation for 4 hr. KNK437
decreased mRNA expression (Figure S6F) and nuclear levels of
both Hsp70 and PDC-E1, compared to vehicle (Figures 6G and
S6G). Nuclear Hsp70 levels correlated positively with nuclear
PDC-E1 levels in both vehicle and KNK437-treated A549 cells
(Figures 6H and S6H). Similar to KNK437, a specific siRNA
against Hsp70 also decreased nuclear levels of both Hsp70
and PDC-E1 in response to serum stimulation (Figure 6I).
Nuclear PDC Is Important for S Phase Entry and Cell-
Cycle Progression
Our data on the dynamic translocation of PDC from the mito-
chondria to the nucleus suggest that it is the same enzymatic
complex that is present in both compartments, rather than
perhaps a different variant. This makes the study of the relative
biological role of PDC on histone acetylation and cell-cycle pro-
gression in the two cellular compartments challenging, particu-
larly in the intact cell setting. We took advantage of PDK’s
localization in mitochondria, but not the nucleus, and designed
experiments in an intact cell setting, in which by subtracting
the effects of selective mitochondrial PDC inhibition (by the
induction of PDK) from the effects of total cellular PDC inhibition
(by PDC-E1 siRNA), we could expose the role of nuclear PDC.
Whereas PDK is already induced in cancer cells, we aimed to
maximally inhibit mitochondrial PDC by two methods: first,
inducing endogenous PDK by activation of HIF1a and, second,
increasing exogenous PDKI via transfection with a PDKI plasmid
(see Figure 7A). With either method, mitochondrial PDC should
be maximally inhibited (condition 1). Then, by inhibiting total
cellular PDC by siRNA gene silencing (condition 2), we could
expose the effects of nuclear PDC on histone acetylation and
cell-cycle progression by subtracting condition 1 from condition
2 (Figure 7A).
For the first experiment, we infected A549 cells with an adeno-
virus encoding for CA5 (AdCA5), a constitutively active mutantform of HIF1a (mHIF1a) (Manalo et al., 2005), avoiding the con-
founding effects of hypoxia. Compared to an adenovirus encod-
ing for LacZ (AdLacZ), increased expression of mHIF1a by
AdCA5 (Figures S7A and S7B) resulted in a significant increase
in the expression of PDKI (Figure 7B) and phosphorylation of
serine-293onmitochondrial,butnotnuclear,PDC-E1 (Figure7C).
Mutant HIF1a increased mitochondrial membrane potential (Fig-
ure S7C), further supporting the mitochondrial PDC suppression
and its impact onmitochondrial function in ourmodel, aswe have
previously described (Bonnet et al., 2007). We then treated
AdCA5-infected cells with scrambled (condition 1) versus PDC-
E1 siRNA (condition 2). We also gave scrambled siRNA to
AdLacZ-infected cells (control). We synchronized all the groups
to theG1phase by serum starvation for 24 hr, followed by reintro-
duction of serum, and 24 hr later, wemeasured S phase markers
and specific histone-3 acetylation sites that are involved in cell-
cycle progression. AdCA5-infected cells treated with scrambled
siRNA had increased acetylation of H3K9 and H3K18, both
important for S phase progression (Cai et al., 2011); increased
G1-S phase progression shown by increased levels of phosphor-
ylated retinoblastoma (P-Rb); as well as elongation-2 factor
(E2F), cyclin A, and cyclin-dependent kinase 2 (Cdk2), markers
for S phase entry, compared to AdLacZ-infected cells treated
with scrambled siRNA (Figure 7D). These effects (condition 1)
are in agreement with the described effects of HIF1a on prolifer-
ation (Semenza, 2010) and the recruitment of histone acetyl
transferases (Luo et al., 2011). In contrast, AdCA5-infected cells
treated with PDC-E1 siRNA (condition 2) had significantly
decreased acetylation of H3K9 and H3K18 and decreased levels
of P-Rb, E2F, cyclin A, and Cdk2 compared to AdCA5-infected
cells treated with scrambled siRNA (condition 1; Figure 7D).
Because both conditions had activated HIF1a and inhibited
mitochondrial PDC, subtraction of condition 2 (gray bars) from
condition 1 (black bars) in Figure 7D shows that nuclear PDC
inhibition decreases Ac-H3K9 and Ac-H3K18 (whereas total H3
levels remain relatively stable) as well as P-Rb and S phase reg-
ulators (E2F, cyclin A, and Cdk2).
For the second experiment, transfection with a PDKI plasmid
increased the expression of PDKI (Figure S7D) and phosphoryla-
tion of PDC-E1 serine-293 (Figure 7E), compared to the empty
vector control. PDKI overexpression did not change histone
acetylation or cell-cycle progression (Figure 7E; compare white
bars [control] to black bars [condition 1]), compatible with the
fact that mitochondrial PDC is significantly inhibited in these
cancer cells at baseline and further inhibition may not elicit any
measurable effects. However, similar to the first experiment,
PDC siRNA (condition 2), decreased H3K9 and H3K18 acetyla-
tion and decreased P-Rb, E2F, cyclin A, and Cdk2, compared
to scrambled siRNA controls (condition 1; Figure 7E). Thus,
two different approaches of inhibiting nuclear PDC support its
role in S phase progression.
DISCUSSION
Here, we show that PDC is present and functional in the nucleus.
Nuclear PDC can generate acetyl-CoA utilized for histone acet-
ylation and S phase entry, providing a link between metabolism
and epigenetic or cell-cycle regulation. This source of nuclearCell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc. 93
Figure 7. Nuclear PDC Is Important for S Phase Entry
(A) Experimental design for the study of nuclear PDC on S phase entry in whole cells (see Results section).
(B andC) AdCA5-treated cells had higher PDKI mRNA levels (n = 3 experiments; *p < 0.01) and higher PDKI protein levels and phosphorylated PDC-E1 serine-293
compared to AdLacZ-treated cells in isolatedmitochondria, but no detectable levels of PDKI were seen in isolated nuclei from both groups compared to AdLacZ-
treated cells (quantification of the immunoblots is shown to the right).
(D) A549 cells treated with AdCA5 (condition 1) followed by scrambled siRNA had increased levels of PDKI; phosphorylated PDC-E1; Ac-H3K9; Ac-H3K18; the
G1-S phase progression marker P-Rb; and the S phase markers elongation-2 factor (E2F), cyclin A, and cyclin-dependent kinase 2 (Cdk2) compared to AdLacZ-
treated scrambled siRNA cells. In contrast, A549 cells treated with AdCA5 followed by PDC-E1 siRNA (condition 2) had decreased levels of both PDC-E1 and
phosphorylated PDC-E1; similar levels of PDK; and decreased levels of Ac-H3K9, Ac-H3K18, P-Rb, E2F, cyclin A, and Cdk2 compared to AdCA5-treated
scrambled siRNA cells (n = 3 experiments; *p < 0.05 versus AdLacZ scr. siRNA; #p < 0.05 versus AdCA5 scr. siRNA).
(E) Transfection with PDKI plasmid followed by PDC-E1 siRNA (condition 2) decreased the levels of PDC-E1, phosphorylated PDC-E1, Ac-H3K9, Ac-H3K18,
P-Rb, E2F, cyclin A, and Cdk2 compared to transfection with PDKI plasmid but treated with scrambled siRNA (condition 1; n = 3 experiments; *p < 0.05 versus
scr. siRNA).
(F) Proposed model for the translocation of PDC from mitochondria to the nucleus and its functional role (see Discussion).
Error bars represent SEM. See also Figure S7.acetyl-CoA may also be important in conditions where the avail-
ability of cytoplasmic citrate (which can cross the nuclear mem-
brane and produce acetyl-CoA through ACL) is decreased due to
suppressed production or shift toward lipid synthesis. Our work
suggests that nuclear PDC has a mitochondrial origin because it
lacks the MLS (which can only be cleaved in the mitochondria),
and its nuclear increase in response to serum is not affected
by inhibition of ribosomal translation. In addition to serum, nu-
clear PDC translocation increases under growth factors (EGF)
or mitochondrial inhibitors (rotenone), suggesting a potential
role in disease states with proliferative signals or mitochondrial
dysfunction, like cancer.
It is intriguing that our data suggest translocation of PDC in the
nucleus, given the large size of this enzymatic complex. High-
resolution electron microscopy and structural analysis have94 Cell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc.recorded its size and diameter within the range of 8–10 MDa
and 25–45 nm, respectively (Sumegi et al., 1987; Zhou et al.,
2001a). However, there is evidence for size and conformational
variability of PDC with identification of complexes as small as 1
MDa (Sumegi et al., 1987; Zhou et al., 2001b). Although the stoi-
chiometry of the individual components in the complex (i.e., the
relative amount of E1, E2, and E3 subunits) varies, in keeping
with the reported variability in its size among tissues, only the
interplay of all subunits within a functional complex can produce
acetyl-CoA. The fact that we find de novo production of acetyl-
CoA in isolated nuclei in response to pyruvate suggests that a
functional complex is present. The fact that we can decrease
the nuclear levels of all subunits by only silencing the gene for
one subunit suggests that the complex travels as a whole from
the mitochondria into the nucleus. PDC was recently identified
as an intact functional complex on the outer mitochondrial
membrane (Hitosugi et al., 2011), suggesting that it can translo-
cate acrossmitochondrial membranes, amore complex process
than translocation across the nuclear membrane. Because the
nuclear pore complex can accommodate the entry of large
complexes of similar diameter to PDC, like ribonucleoprotein
complexes (Lodish et al., 2000) or intact nucleocapsids of
viruses (Pante´ and Kann, 2002), it is possible that an intact
PDC complex could translocate to the nucleus.
We provide evidence that Hsp70 may promote the nuclear
translocation of a constitutively active form of PDC. By
competing with PDK for binding to PDC, Hsp70 may allow
PDC to remain active when translocated to the nucleus (Fig-
ure 7F). Kiang et al. (2006) showed that Hsp70 binds to and
activates mitochondrial PDC, but did not show the mechanism
of this activation. It may be that, by competing with PDK,
Hsp70 inhibits the binding of this inhibitory kinase and thus
activates PDC. It is possible that EGF can promote nuclear acet-
ylation by a coordinated translocation of PKM2 and PDC, poten-
tially by increasing Hsp70 levels (Milarski and Morimoto, 1986;
Figure 7F). This model may contribute to the recently described
effects of nuclear PKM2 on tumor growth via histone acetylation,
offering a source and mechanism for the nuclear acetyl-CoA
generation used for the acetylation of H3K9 (Yang et al., 2012).
It is appealing to consider that there is a mechanism by which
several factors required for the nuclear response to proliferative
stimuli (for example PKM2 and PDC) can be transferred simulta-
neously, increasing efficiency. Although our collective data sup-
port the existence of the translocation model shown in Figure 7F,
we cannot rule out the possibility that individual subunits may be
transported independently in the nucleus, where they could
potentially be assembled in an intact complex with the help of
a chaperone, like Hsp70.
Tyrosine phosphorylation by growth factor signaling,
including EGFR, activates PDKI, providing a mechanism for
suppression of mitochondrial PDC in cancer (Hitosugi et al.,
2011), in addition to the induction of PDK expression by
HIF1a (Kim et al., 2006). Therefore, in a ‘‘double hit’’ manner,
EGF stimulation can activate PDK, suppressing mitochondrial
PDC (which has been shown to inhibit mitochondria-dependent
apoptosis in cancer; Bonnet et al., 2007) in tandem with Hsp70-
mediated nuclear translocation of PDC, promoting histone
acetylation and cell-cycle progression (Figure 7F). The inhibition
of PDK by siRNA, DCA, or hybrid drugs (like mitoplatin, a drug
that structurally combines cisplatin with DCA molecules; Dhar
and Lippard, 2009) decreases cancer growth in animal models
(Bonnet et al., 2007) and a small human trial (Michelakis et al.,
2010) by activating glucose oxidation, reversing the Warburg
effect and the resistance to apoptosis in cancer cells. Our
work now suggests that the nuclear pool of PDC is ‘‘immune’’
to this strategy. It raises the possibility that, in response to
these interventions, cancer cells may ‘‘escape’’ by promoting
a transfer of PDC in the nucleus, where PDC may promote pro-
liferation. It also suggests that anticancer strategies, in which
PDK inhibition is used, may perhaps be strengthened by simul-
taneous inhibition of EGFR signaling or Hsp70 function. As PDC
plays a prominent role in many metabolic disorders, it will be
important for scientists to be aware that their efforts to targetPDC may have direct and previously unrecognized effects on
nuclear biology.
Our work suggests an alternative pathway to ACL for the
nucleus to generate acetyl-CoA for histone acetylation. It is
possible that, in specific tissues or disease states, the relative
importance of ACL or nuclear PDC may be different. ACL has
been shown to be important for histone acetylation during
differentiation (Wellen et al., 2009), whereas our work suggests
that histone acetylation by nuclear PDC may be important for
cell-cycle progression. ACL and PDC should be studied together
when assessing histone acetylation and epigenetic regulation in
conditions in which both differentiation and proliferation are
taking place, including development, cancer, and other prolifer-
ative conditions or stem cell biology.
EXPERIMENTAL PROCEDURES
For additional details, see Extended Experimental Procedures.
Cell Culture
Human A549 non-small-cell lung cancer cells, 786-O renal cell carcinoma,
and MRC-9 fibroblasts were purchased from ATCC. A549 cells were main-
tained on F12K medium, whereas 786-O cells in RPMI-1640 media and
MRC-9 cells in Eagle’s minimal essential medium (EMEM). Primary human
fibroblasts were isolated from the lung of a transplant patient in accordance
with the Human Ethics Committee at the University of Alberta and maintained
in Dulbecco’s modified Eagle’s medium (DMEM). Human SAECs were
purchased from ScienCell and maintained in SAEpiCM, provided by the com-
pany. Media for all cell lines were supplemented with 10% fetal bovine serum
(FBS) (unless stated otherwise) and 5% antibiotic and antimycotic (Invitrogen-
Gibco Canada).
Confocal Microscopy
Confocal microscopy was performed using a two-photon Zeiss LSM 510
NLO model (Carl Zeiss). All images were scanned in midplane of the cell in
the z axis as shown in Figure 1D, using a 1003 numerical aperture (NA) 1.3
oil objective lens at 23 zoom, allowing for a pixel size of 0.04 3 0.04 3
0.2 mm. Fluorophore-conjugated secondary antibodies (Dako, Invitrogen,
and Molecular Probes) and the nuclear stain DAPI (Molecular Probes) were
used for immunofluorescence imaging with specific excitations of 488 nm
(Fitc), 543 (Tritc), 633 (Far Red), and 750 nm; two photon (DAPI) and the corre-
sponding emissions were detected with the following filter sets. Fitc: band
pass (BP) 505–535; Tritc: BP 565–615; Far red: high pass (LP) 650; and
DAPI: BP 390–465. Overlap was eliminated between the emissions of any
secondary antibodies, mitochondrial-specific dyes, EGFP, and nuclear stains
by imaging each channel independently and sequentially with only one excita-
tion wavelength active during each scan.
Mass Spectrometry for 13C1-acetyl-CoA
Isolated nuclei from scrambled and PDC-E1 siRNA-treated cells were
exposed to13C2-pyruvate (Cambridge Isotope Laboratories) for 8 hr, before
the experiment was terminated with the addition of ice-cold storage
buffer. Metabolites were extracted and 30 ml of samples was diluted to
120 ml with methanol and flow injected to the mass spectrometry (MS) using
4000 QTRAP mass spectrometer (AB Sciex) with either enhanced product
ion (EPI; IonSpray voltage of 4,500 V) or enhanced MS (EMS; IonSpray
voltage of 5,500 V).
Immunoblotting
Immunoblotting with standard SDS-PAGE was performed as previously
described (Bonnet et al., 2007). Where required, SDS-PAGE of purified his-
tones as well as nuclear, mitochondrial, and cellular protein was performed
on 16.5% Tricine gels (Bio-Rad) followed by immunoblotting to low-pore-
size (0.2 mm) nitrocellulose (Bio-Rad).Cell 158, 84–97, July 3, 2014 ª2014 Elsevier Inc. 95
Statistical Analysis
Unpaired Student’s t test was used for statistical calculations when com-
paring the effects of treatment between two sample groups. Error bars
indicate SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two movies and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.04.046.
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